Austin Health

Title
Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey.
Publication Date
2021-07-09
Author(s)
Yeung, Emily
Bello, A K
Levin, Adeera
Lunney, Meaghan
Osman, Mohamed A
Ye, Feng
Ashuntantang, Gloria
Bellorin-Font, Ezequiel
Benghanem Gharbi, Mohammed
Davison, Sara
Ghnaimat, Mohammad
Harden, Paul
Jha, Vivekanand
Kalantar-Zadeh, Kamyar
Kerr, Peter
Klarenbach, Scott
Kovesdy, Csaba
Luyckx, Valerie
Neuen, Brendon
O'Donoghue, Donal
Ossareh, Shahrzad
Perl, Jeffrey
Ur Rashid, Harun
Rondeau, Eric
See, Emily J
Saad, Syed
Sola, Laura
Tchokhonelidze, Irma
Tesar, Vladimir
Tungsanga, Kriang
Turan Kazancioglu, Rumeyza
Wang, Angela Yee-Moon
Wiebe, Natasha
Yang, Chih-Wei
Zemchenkov, Alexander
Zhao, Minhui
Jager, Kitty J
Caskey, Fergus
Perkovic, Vlado
Jindal, Kailash
Okpechi, Ikechi G
Tonelli, Marcello
Feehally, John
Harris, David Ch
Johnson, David
Subject
chronic renal failure
dialysis
end stage renal failure
epidemiology
health economics
organisation of health services
Type of document
Journal Article
OrcId
0000-0002-1244-1044
0000-0003-4954-0529
0000-0003-4513-6449
0000-0002-6545-9715
0000-0002-0846-3187
DOI
10.1136/bmjopen-2020-047245
Abstract
The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. A cross-sectional global survey. Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. 160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries.
Link
Citation
BMJ Open 2021; 11(7): e047245
Jornal Title
BMJ Open

Files:

NameSizeformatDescriptionLink